Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD of Vaxxinity, Inc. from Q4 2019 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Vaxxinity, Inc. quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents history and change rate from Q4 2019 to Q4 2023.
  • Vaxxinity, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending 31 Dec 2023 was $5.04M, a 85.4% decline year-over-year.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Change (%)

Vaxxinity, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (USD)

Period Value YoY Chg Change % Date Report Filed
Q4 2023 $5.04M -$29.5M -85.4% 31 Dec 2023 10-K 27 Mar 2024
Q3 2023 $17.6M -$4.35M -19.8% 30 Sep 2023 10-Q 08 Nov 2023
Q2 2023 $37.3M -$76.5M -67.2% 30 Jun 2023 10-Q 09 Aug 2023
Q1 2023 $22.7M -$102M -81.8% 31 Mar 2023 10-Q 09 May 2023
Q4 2022 $34.6M -$110M -76.2% 31 Dec 2022 10-K 27 Mar 2024
Q3 2022 $21.9M -$67.5M -75.5% 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 $114M +$2.87M +2.59% 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 $125M +$75.6M +154% 31 Mar 2022 10-Q 09 May 2023
Q4 2021 $145M +$114M +365% 31 Dec 2021 10-K 27 Mar 2024
Q3 2021 $89.4M +$71.2M +390% 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 $111M 30 Jun 2021 10-Q 11 Aug 2022
Q1 2021 $49.2M 31 Mar 2021 10-Q 09 May 2022
Q4 2020 $31.2M +$30.7M +6454% 31 Dec 2020 10-K 27 Mar 2023
Q3 2020 $18.2M 30 Sep 2020 10-Q 23 Dec 2021
Q4 2019 $476K 31 Dec 2019 10-K 24 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.